DOCSLIB.ORG

Consumer Product Safety Commission § 1702.12

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Consumer Product Safety Commission § 1702.12 Consumer Product Safety Commission § 1702.2 CFR 1700.1(b)(2)), the term household AUTHORITY: 15 U.S.C. 1471(4), 1472, 1474, substance is defined as ‘‘any substance 1269(a), 2079(a); 21 U.S.C. 371(a). which is customarily produced or dis- SOURCE: 45 FR 13064, Feb. 28, 1980, unless tributed for sale for consumption or otherwise noted. use, or customarily stored, by individ- uals in or about the household * * *.’’ § 1702.1 Purpose and policy. The Commission has issued require- (a) Section 1700.14(a) of part 1700 lists ments for special packaging for certain household substances the Consumer hazardous substances at 16 CFR Product Safety Commission requires, 1700.14(a). Unless otherwise indicated in under section 3(a)(1) of the Poison Pre- the requirements for specific hazardous vention Packaging Act of 1970, 15 substances, the Commission interprets U.S.C. 1472, to be contained in special the term ‘‘household substance’’ as packaging to protect children from se- only applying to these hazardous sub- stances when packaged in containers rious personal injury or serious illness with a capacity of less than 5 gallons. resulting from handling, using, or in- As a result, unless otherwise specified, gesting such substances. There may be the hazardous substances at 16 CFR occasions, however, when the Commis- 1700.14(a) are not required to be in spe- sion determines that a particular sub- cial packaging when packaged in con- stance should be exempt from special tainers of 5 gallons or more. packaging requirements. (b) The Commission may, either on (Secs. 2, 5, 7, 9, Pub. L. 91–601; 94 Stat. 1670– its own initiative or upon the petition 1674 (15 U.S.C. 1471, 1474, 1476, 1478); sec. 30(a), Pub. L. 92–573, 86 Stat. 1231 (15 U.S.C. 2079(a)) of any interested person, amend the regulation at § 1700.14(a) by exempting [43 FR 53712, Nov. 17, 1978] a substance or category of substances from special packaging requirements. PART 1702—PETITIONS FOR EXEMP- The purpose of these rules is to provide TIONS FROM POISON PREVEN- procedures and requirements for sub- TION PACKAGING ACT REQUIRE- mitting petitions for exemption from MENTS; PETITION PROCEDURES special packaging requirements. AND REQUIREMENTS § 1702.2 Procedural requirements and Sec. recommendations. 1702.1 Purpose and policy. (a) Requirements. To be considered a 1702.2 Procedural requirements and rec- petition for exemption from special ommendations. packaging requirements under this 1702.3 Substantive requirements. 1702.4 Petitions with insufficient or incom- part a document filed under this part plete information. must: 1702.5 Failure to supply adverse informa- (1) Be mailed to the Office of the Sec- tion. retary, Consumer Product Safety Com- 1702.6 Trade secrets and other confidential mission, Washington, D.C. 20207, or de- information. livered to the Office of the Secretary, 1702.7 Justification for the exemption. 1702.8 Human experience data. Consumer Product Safety Commission, 1702.9 Relevant experimental data. 4330 East West Highway, Bethesda, MD 1702.10 Human experimental data involving 20814, the testing of human subjects. (2) Be written in the English lan- 1702.11 Product specifications. guage, 1702.12 Packaging specifications. (3) Contain the name and address of 1702.13 Labeling and packaging samples. 1702.14 Marketing history. the petitioner, 1702.15 Petitions alleging the incompati- (4) Contain an explicit request for ex- bility of child resistant packaging with emption from special packaging re- the particular substance petitioned for quirements, exemption. (5) Identify the category of sub- 1702.16 Petitions requesting an exemption stances under § 1700.14(a) from which for a drug or a new drug. 1702.17 Granting petitions. the exemption is sought, and 1702.18 Denying petitions. (6) Identify the particular substance 1702.19 Effect of filing petition. for which the exemption is sought. 919 VerDate Sep<11>2014 14:34 Sep 15, 2021 Jkt 253055 PO 00000 Frm 00929 Fmt 8010 Sfmt 8010 Q:\16\16V2.TXT PC31 kpayne on VMOFRWIN702 with $$_JOB § 1702.3 16 CFR Ch. II (1–1–21 Edition) (b) Failure to meet requirements. Where § 1702.4 Petitions with insufficient or a submission fails to meet all of the re- incomplete information. quirements of paragraph (a) of this sec- If a petition is submitted that is not tion, the Office of the Secretary shall complete and does not explain the rea- notify the person submitting it, de- son for the absence of the information, scribe the deficiency, and explain that the Commission shall afford the peti- the petition may be resubmitted when tioner a reasonable opportunity to pro- the deficiency is corrected. vide additional information. If the re- (c) Procedural recommendations. The quired information is not submitted to following are procedural recommenda- the Commission, or if the petitioner tions to help the Commission in its does not satisfactorily explain the ab- consideration of petitions. The Com- sence of the information within a rea- mission requests, but does not require, sonable time, the petition shall be that petitions filed under this part: closed if insufficient or incomplete in- (1) Be typewritten, formation has been submitted to en- (2) Include the word ‘‘petition’’ in a able the Commission to evaluate the heading preceding the text, merits of the exemption request. (3) Include the telephone number of the petitioner, and § 1702.5 Failure to supply adverse in- formation. (4) Be accompanied by at least five (5) copies of the petition. Failure to obtain and provide the Commission with all reasonably avail- [45 FR 13064, Feb. 28, 1980, as amended at 62 able information that the petitioner FR 46668, Sept. 4, 1997] knows is unfavorable or could reason- ably expect to be unfavorable to the pe- § 1702.3 Substantive requirements. tition shall result in the denial of the (a) A petition filed under this part petition. shall include the information required by this part, or a satisfactory expla- § 1702.6 Trade secrets and other con- nation for the absence of the informa- fidential information. tion. As provided by § 1702.4, a petition Where a petition contains material which is not complete may be closed. that the petitioner believes should be To be considered complete, a petition exempt from public disclosure under shall include the following: the Freedom of Information Act, 5 (1) A statement of the justification U.S.C. 552, the petitioner shall comply for the exemption in accordance with with the requirements of 16 CFR part § 1702.7, 1015, the Commission’s regulation (2) All reasonably available human under the Freedom of Information Act experience data, reasonably available concerning requests for treatment as relevant experimental data (both exempt material. The Commission human and animal), product and pack- shall act upon any request for treat- aging specifications, labeling, and mar- ment as exempt material in accordance keting history, in accordance with with the provisions of 16 CFR part 1015. §§ 1702.8 through 1702.14, (b) As used in this regulation, ‘‘rea- § 1702.7 Justification for the exemp- sonably available’’ information is data tion. in the petitioner’s possession; data The justification for the exemption, that has previously been generated by required under § 1702.3, shall explain the petitioner, and data that is obtain- the reason for the exemption based on able from such sources as: Reports one or more of the following grounds: from Poison Control Centers; reports of (a) If the justification is based on a adverse reactions that have been sub- lack of need for special packaging to mitted to the petitioner; the medical, protect young children from serious in- pharmacological, and toxicological lit- jury or illness from the substance, the erature; and information required by justification shall state how the lack of the FDA for an Investigational Exemp- toxicity and lack of adverse human ex- tion for a New Drug (IND) or a New perience for the substance clearly sup- Drug Application (NDA). ports granting the exemption. 920 VerDate Sep<11>2014 14:34 Sep 15, 2021 Jkt 253055 PO 00000 Frm 00930 Fmt 8010 Sfmt 8010 Q:\16\16V2.TXT PC31 kpayne on VMOFRWIN702 with $$_JOB Consumer Product Safety Commission § 1702.9 (b) If the exemption is requested be- mal body. Therefore, the Commission cause special packaging is not techno- considers experimental data obtained logically feasible, practicable, or ap- in animal studies to be an important propriate for the substance, the jus- supplement to such data as may exist tification shall explain why. from any experimental studies con- (c) If the exemption is requested be- ducted in humans. The minimum toxi- cause special packaging is incompat- cological evaluation necessary for a ible with the particular substance, the particular household substance is pro- justification shall explain why. portional to the expected exposure of man to that substance. Household sub- § 1702.8 Human experience data. stances which are not expected, in nor- Human experience data constitutes mal use, to contact man are subject to the primary criterion used by the Com- less extensive studies than those sub- mission in evaluating petitions for ex- stances, such as drugs, which are de- emptions. Petitions shall therefore in- signed to be used in or on man. The clude a compilation of all reasonably Commission has, therefore, separated available reports pertaining to human the requirements of this section into use of the particular substance, includ- three subsections. Section 1702.9(a) ing the product brand as well as ge- lists minimum acute animal toxicity neric equivalents and involving adverse data which shall be submitted, if rea- reports of personal injury, illness, and sonably available, for all petitions; significant allergenicity. Such infor- § 1702.9(b) lists those additional data mation in children is of particular im- which shall be submitted, if reasonably portance in evaluating exemption re- available, for drug products and all quests.
Load more

Recommended publications
  • The Excretion and Storage of Ammonia by the Aquatic Larva of Sialis Lutaria (Neuroptera)
    THE EXCRETION AND STORAGE OF AMMONIA BY THE AQUATIC LARVA OF SIALIS LUTARIA (NEUROPTERA) BY B. W. STADDON* Department of Zoology, University of Durham, King's College, Newcastle upon Tyne (Received 12 April 1954) INTRODUCTION Delaunay (1931), in a review of the invertebrates, showed that an excellent correla- tion existed between the nature of the major nitrogenous component of the excreta and the nature of the environment, aquatic or terrestrial, in which an animal lived. Ammonia was shown to predominate in the excreta of aquatic species, urea or uric acid in the excreta of semi-terrestrial or terrestrial species. Delaunay put forward the view that the synthesis by these terrestrial forms of more complex molecules from ammonia was essentially a detoxication mechanism necessitated by a restricted water supply. Although the insects are primarily a terrestrial group, representatives of a number of orders have become aquatic in one or more stages of their life histories. It is well known that those terrestrial species which have been examined, with the notable exception of blowfly larvae, excrete the bulk of their nitrogen in the form of uric acid (Wigglesworth, 1950). The possibility, however, that aquatic species might have reverted to ammonotelism does not seem to have been examined. Preliminary tests were carried out on the excreta of a variety of aquatic insects. In all cases ammonia was found to be the major nitrogenous excretory product. An investigation into various aspects of the metabolism, toxicity and excretion of ammonia was then undertaken on the aquatic larva of Siatis lutaria. It is the purpose of the present communication to present some observations on the excretion and storage of ammonia in this species.
    [Show full text]
  • In Vitro Interactions of Epacadostat and Its Major Metabolites With
    DMD Fast Forward. Published on March 10, 2017 as DOI: 10.1124/dmd.116.074609 This article has not been copyedited and formatted. The final version may differ from this version. DMD # 74609 In vitro interactions of epacadostat and its major metabolites with human efflux and uptake transporters: Implications for pharmacokinetics and drug interactions Qiang Zhang, Yan Zhang, Jason Boer, Jack G. Shi, Peidi Hu, Sharon Diamond, and Downloaded from Swamy Yeleswaram Incyte Corporation, Wilmington, DE 19803 dmd.aspetjournals.org at ASPET Journals on September 29, 2021 1 DMD Fast Forward. Published on March 10, 2017 as DOI: 10.1124/dmd.116.074609 This article has not been copyedited and formatted. The final version may differ from this version. DMD # 74609 Running title: Interactions of Epacadostat with Transporters Corresponding Author: Qiang Zhang, Ph.D. Incyte Corporation 1801 Augustine Cut-Off Wilmington, DE 19803 Downloaded from Email: [email protected] Phone: 302-498-5827 Fax: 302-425-2759 dmd.aspetjournals.org Number of Text Pages: 24 Number of Figures: 8 at ASPET Journals on September 29, 2021 Number of Tables: 6 Number of References: 24 The number of words of Abstract: 247 The number of words of Introduction: 655 The number of words of Discussion: 1487 Non-standard Abbreviations: EPAC, epacadostat; IDO1, indoleamine 2,3-dioxygenase 1; EHC, enterohepatic circulation; NME, new chemical entity; TEER, transepithelial electrical resistance; HBSS, Hank's Balanced Salt Solution; KO, knockout; CSA, cyclosporin A; IC50, half-maximal inhibitory concentration; ER, efflux ratio 2 DMD Fast Forward. Published on March 10, 2017 as DOI: 10.1124/dmd.116.074609 This article has not been copyedited and formatted.
    [Show full text]
  • TOXICOLOGY and EXPOSURE GUIDELINES ______(For Assistance, Please Contact EHS at (402) 472-4925, Or Visit Our Web Site At
    (Revised 1/03) TOXICOLOGY AND EXPOSURE GUIDELINES ______________________________________________________________________ (For assistance, please contact EHS at (402) 472-4925, or visit our web site at http://ehs.unl.edu/) "All substances are poisons; there is none which is not a poison. The right dose differentiates a poison and a remedy." This early observation concerning the toxicity of chemicals was made by Paracelsus (1493- 1541). The classic connotation of toxicology was "the science of poisons." Since that time, the science has expanded to encompass several disciplines. Toxicology is the study of the interaction between chemical agents and biological systems. While the subject of toxicology is quite complex, it is necessary to understand the basic concepts in order to make logical decisions concerning the protection of personnel from toxic injuries. Toxicity can be defined as the relative ability of a substance to cause adverse effects in living organisms. This "relative ability is dependent upon several conditions. As Paracelsus suggests, the quantity or the dose of the substance determines whether the effects of the chemical are toxic, nontoxic or beneficial. In addition to dose, other factors may also influence the toxicity of the compound such as the route of entry, duration and frequency of exposure, variations between different species (interspecies) and variations among members of the same species (intraspecies). To apply these principles to hazardous materials response, the routes by which chemicals enter the human body will be considered first. Knowledge of these routes will support the selection of personal protective equipment and the development of safety plans. The second section deals with dose-response relationships.
    [Show full text]
  • Biotransformation: Basic Concepts (1)
    Chapter 5 Absorption, Distribution, Metabolism, and Elimination of Toxics Biotransformation: Basic Concepts (1) • Renal excretion of chemicals Biotransformation: Basic Concepts (2) • Biological basis for xenobiotic metabolism: – To convert lipid-soluble, non-polar, non-excretable forms of chemicals to water-soluble, polar forms that are excretable in bile and urine. – The transformation process may take place as a result of the interaction of the toxic substance with enzymes found primarily in the cell endoplasmic reticulum, cytoplasm, and mitochondria. – The liver is the primary organ where biotransformation occurs. Biotransformation: Basic Concepts (3) Biotransformation: Basic Concepts (4) • Interaction with these enzymes may change the toxicant to either a less or a more toxic form. • Generally, biotransformation occurs in two phases. – Phase I involves catabolic reactions that break down the toxicant into various components. • Catabolic reactions include oxidation, reduction, and hydrolysis. – Oxidation occurs when a molecule combines with oxygen, loses hydrogen, or loses one or more electrons. – Reduction occurs when a molecule combines with hydrogen, loses oxygen, or gains one or more electrons. – Hydrolysis is the process in which a chemical compound is split into smaller molecules by reacting with water. • In most cases these reactions make the chemical less toxic, more water soluble, and easier to excrete. Biotransformation: Basic Concepts (5) – Phase II reactions involves the binding of molecules to either the original toxic molecule or the toxic molecule metabolite derived from the Phase I reactions. The final product is usually water soluble and, therefore, easier to excrete from the body. • Phase II reactions include glucuronidation, sulfation, acetylation, methylation, conjugation with glutathione, and conjugation with amino acids (such as glycine, taurine, and glutamic acid).
    [Show full text]
  • Absorption, Distribution, Metabolism, Excretion and Toxicology Dr
    Draft Guidance Novel Foods Absorption, Distribution, Metabolism, Excretion and Toxicology Dr. Josef Schlatter Member of the Scientific Committee and EFSA’s WG on Novel Foods Stakeholder Meeting, 11 April 2016, Brussels Section 7 Absorption, Distribution, Metabolism, and Excretion (ADME) 2 7. ADME (1) Critical for the development of appropriate toxicity testing strategy including the selection of appropriate animal models. Important information for the interpretation of study results. Differences between experimental animals and humans. Consider tiered approach to toxicokinetic testing which are described in section 4.1 on « Toxicokinetics (ADME) » of the EFSA Guidance for food additive evaluations (EFSA ANS Panel, 2012). Negligible absorption may provide a scientific justification for not undertaking higher tiered toxicological studies. Single substances and simple mixtures should normally be tested according to the same principles as those applied to food additives. As a default, absorption of the Novel Food or its breakdown products should be assessed. 3 7. ADME (2) For food additives in the form of complex mixtures, the ANS Guidance states that «conventional metabolism and toxicokinetic studies may not be feasible for all components in the mixture, but should be provided for toxicologically relevant constituents. Toxicologically relevant constituents are generally considered to be the major components and those other components with known or demonstrable biological or toxicological activity, and should be determined on a case-by-case basis with a scientific justification and the rationale for their selection provided ». Whole foods should be tested like complex mixtures as stated in the ANS Guidance. 4 7. ADME (3) For Novel Foods, ADME assessment should also address nutritionally significant constituents where toxicokinetic data on these constituents are important considerations for the evaluation of the nutritional impact of the Novel Food.
    [Show full text]
  • Pharmacology Part 2: Introduction to Pharmacokinetics
    J of Nuclear Medicine Technology, first published online May 3, 2018 as doi:10.2967/jnmt.117.199638 PHARMACOLOGY PART 2: INTRODUCTION TO PHARMACOKINETICS. Geoffrey M Currie Faculty of Science, Charles Sturt University, Wagga Wagga, Australia. Regis University, Boston, USA. Correspondence: Geoff Currie Faculty of Science Locked Bag 588 Charles Sturt University Wagga Wagga 2678 Australia Telephone: 02 69332822 Facsimile: 02 69332588 Email: [email protected] Foot line: Introduction to Pharmacokinetics 1 Abstract Pharmacology principles provide key understanding that underpins the clinical and research roles of nuclear medicine practitioners. This article is the second in a series of articles that aims to enhance the understanding of pharmacological principles relevant to nuclear medicine. This article will build on the introductory concepts, terminology and principles of pharmacodynamics explored in the first article in the series. Specifically, this article will focus on the basic principles associated with pharmacokinetics. Article 3 will outline pharmacology relevant to pharmaceutical interventions and adjunctive medications employed in general nuclear medicine, the fourth pharmacology relevant to pharmaceutical interventions and adjunctive medications employed in nuclear cardiology, the fifth the pharmacology related to contrast media associated with computed tomography (CT) and magnetic resonance imaging (MRI), and the final article will address drugs in the emergency trolley. 2 Introduction As previously outlined (1), pharmacology is the scientific study of the action and effects of drugs on living systems and the interaction of drugs with living systems (1-7). For general purposes, pharmacology is divided into pharmacodynamics and pharmacokinetics (Figure 1). The principle of pharmacokinetics is captured by philosophy of Paracelsus (medieval alchemist); “only the dose makes a thing not a poison” (1,8,9).
    [Show full text]
  • Isoxaflutole
    ISOXAFLUTOLE First draft prepared by P.V. Shah 1 and Roland Alfred Solecki 2 1 Office of Pesticide Programs, Environmental Protection Agency, Washington, DC, United States of America (USA) 2 Federal Institute for Risk Assessment, Berlin, Germany Explanation ........................................................................................................................................... 393 Evaluation for acceptable daily intake .................................................................................................. 394 1. Biochemical aspects ............................................................................................................... 394 1.1 Absorption, distribution and excretion ............................................................................ 394 1.2 Biotransformation ........................................................................................................... 397 1.3 Dermal absorption ........................................................................................................... 399 2. Toxicological studies ............................................................................................................. 400 2.1 Acute toxicity .................................................................................................................. 400 (a) Oral administration .................................................................................................. 401 (b) Dermal application ..................................................................................................
    [Show full text]
  • Clinical Pharmacology Elimination of Drugs
    BRITISH MEDICAL JOURNAL VOLUME 282 7 MARCH 1981 809 Br Med J (Clin Res Ed): first published as 10.1136/bmj.282.6266.809 on 7 March 1981. Downloaded from Today's Treatment Clinical pharmacology Elimination of drugs H E BARBER, J C PETRIE This article outlines the principles ofdrug elimination, principally influenced by the lipid solubility of the drug. The more lipid by the liver and kidneys. Most elimination processes of drugs soluble the drug is, the more distribution into lipid compart- follow first-order elimination kinetics. In such processes a ments takes place and hence the larger is the Vd of the drug, defined and constant fraction of a drug-for example, half-is thus affecting its elimination. irreversibly eliminated in a constant time. The half-life time (t1) Drug clearance is also influenced by the rate of delivery of the in such first-order processes is the time taken for the concen- drug to the organs of elimination, principally the liver and tration of the drug to fall to half its previous value, regardless kidney, and by the capacity of the organs to eliminate the drug. of the initial concentration of the drug. Some drugs-for In clinical practice most drugs are swallowed and with some, example, ethyl alcohol-follow zero-order elimination kinetics. for example, propranolol, the bioavailability is low because only In these processes elimination of the drug occurs at a constant a fraction of the oral dose administered reaches the systemic rate, because the enzymes responsible for metabolism of drugs, circulation due to extensive presystemic or first-pass elimination and the active excretion processes particularly in the kidney, during absorption from the gut and passage through the liver.
    [Show full text]
  • Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid
    pharmaceutics Article Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid Yun Ju Kang 1, Chul Haeng Lee 2, Soo-Jin Park 3, Hye Suk Lee 4 , Min-Koo Choi 2,* and Im-Sook Song 1,5,* 1 College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea; [email protected] 2 College of Pharmacy, Dankook University, Cheonan 31116, Korea; [email protected] 3 College of Korean Medicine, Daegu Haany University, Daegu 38610, Korea; [email protected] 4 College of Pharmacy, The Catholic University of Korea, Bucheon 14662, Korea; [email protected] 5 BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, Kyungpook National University, Daegu 41566, Korea * Correspondence: [email protected] (M.-K.C.); [email protected] (I.-S.S.); Tel.: +82-41-550-1438 (M.-K.C.); +82-53-950-8575 (I.-S.S.); Fax: +82-53-950-8557 (I.-S.S.) Abstract: We investigated the involvement of drug transporters in the pharmacokinetics of ros- marinic acid in rats as well as the transporter-mediated drug interaction potential of rosmarinic acid in HEK293 cells overexpressing clinically important solute carrier transporters and also in rats. Intravenously injected rosmarinic acid showed bi-exponential decay and unchanged rosmarinic acid was mainly eliminated by urinary excretion, suggesting the involvement of transporters in its renal excretion. Rosmarinic acid showed organic anion transporter (OAT)1-mediated active transport with a Km of 26.5 µM and a Vmax of 69.0 pmol/min in HEK293 cells overexpressing OAT1, and the plasma concentrations of rosmarinic acid were increased by the co-injection of probenecid because of decreased renal excretion due to OAT1 inhibition.
    [Show full text]
  • Module Two Routes of Exposure
    Module Two Routes of Exposure 90 Module Two Routes of Exposure Time Allotted: 60 Minutes Objectives: Upon completion of this module, the learner will be able to # Define and understand the types of environments # Identify the protective barriers of the body # Identify the routes of exposure # Identify the pathways for exposure # Identify the types of exposures # Understand local and systemic exposures # Identify the pathways for excretion of toxins 91 Presentation Outline I. Introduction - Types of Environments A. Inner versus Outer Environment B. Personal versus Ambient Environment C. Gaseous, Liquid, and Solid Environments D. Chemical, Biological, Physical, and Socioeconomic Environments II. Routes of Exposure A. Dermal absorption B. Inhalation C. Ingestion D. Other Routes of Exposure III. Elements for a Pathway of Exposure A. Source of contamination B. Media for contaminant travel C. Point of Exposure D. Route of Exposure E. Receptor Population IV. Types of Exposure A. Acute B. Chronic C. Sub-acute D. Sub-chronic V. Effects After Exposure A. Local B. Systemic VI. Excretion of Toxins A. Urine B. Liver C. Lungs VII. Test Your Knowledge Quiz 92 VIII. Activity Lab IX. Question and Answer Period 93 Lecture Notes I. Types of Environments Before one can understand the routes and pathways of exposure, it is important to have an understanding of the term “environment.” Environment can be defined in a number of ways (7): # Inner versus outer environment # Personal versus ambient environment # Gaseous, liquid, and solid environments # Chemical, biological, physical, and socioeconomic environments A. Inner Versus Outer Environment This refers to the human body and consists of the environment within the body and the environment outside of the body.
    [Show full text]
  • Pharmacokinetics: the Absorption, Distribution, and Excretion of Drugs
    Chapter 3 Pharmacokinetics: % C The Absorption, . 789—. Distribution, and 4 5 6 X Excretion of Drugs 1 2 3 – 0 • = + OBJECTIVES After studying this chapter, the reader should be able to: • Explain the meaning of the terms absorption, distribu- tion, metabolism, and excretion. • List two physiologic factors that can alter each of the KEY TERMS processes of absorption, distribution, and excretion. • achlorhydria • adipose • Explain how bioavailability can impact drug response • albumin and product selection. • aqueous • Compare the roles of passive diffusion and carrier-medi- • bioavailability ated transport in drug absorption. • bioequivalent • biotransformation • Describe two types of drug interaction and explain how • blood-brain barrier they might affect drug response and safety. • capillary permeability • cardiac decompen- sation • carrier-mediated transport • catalyze • concentration gradient • dissolution • distribution • epithelium • equilibrium • excretion 27 28 Practical Pharmacology for the Pharmacy Technician • extracellular • lipids • prodrug • first-pass effect • metabolism • saturable process • hydrophilic • metabolite • steady state • interstitial • passive diffusion • volume of distribution • intracellular distribution The process by Safe and effective drug treatment is not only a function of the physical and chemical prop- which a drug is carried to erties of drugs, but also a function of how the human body responds to the administration sites of action throughout of medication. The study of the bodily processes that affect the movement of a drug in the the body by the blood- body is referred to as pharmacokinetics. To understand the pharmacology of drugs, the stream. pharmacy technician must also understand the four fundamental pathways of drug move- ment and modification in the body (Fig. 3.1). First, drug absorption from the site of admin- metabolism The total of all istration permits entry of the compound into the blood stream.
    [Show full text]
  • Table 13. Drug Metabolism Basics Bioavailability and Half-Life: Cannot
    Table 13. Drug Metabolism Basics Bioavailability and Half-Life: Cannot predict bioavailability and half-life on just one pharmacokinetic parameter Absorption: What proportion (percent) of an oral drug gets from the GI tract into the blood? Distribution: Where does the drug go? • Lipophilic = distributes through membranes with preference for adipose tissue and muscle (greater volume of distribution) • Hydrophilic = remains mostly in blood compartment until the drug is eliminated • An increase in the volume of distribution of a drug will generally increase its elimination half-life • A decrease in volume of distribution with an increase in elimination clearance will generally decrease elimination half-life Metabolism: How is the drug changed so it can be excreted? • The quicker the metabolism, the shorter the half-life • The liver is the major site for drug metabolism, but biotransformation can also occur by the kidney and intestine • Conversion of lipophilic drugs to more polar metabolites by the liver may increase excretion in the bile and kidney, and thus may decrease half-life Excretion: How does the drug leave the blood (e.g. urine)? • The quicker the excretion, the shorter the half-life • Polar, hydrophilic drugs may have increased excretion in the urine Lipophilic drugs More likely to be metabolized, creating metabolites that are likely more polar, and then more easily excreted. • Phase 1 = Convert lipophilic molecules into more polar molecules (hydrolysis, oxidation, reduction) • Phase 2 = Further convert lipophilic molecules into more polar molecules through conjugation with glucuronic acid, sulfuric acid, acetic acid, or amino acid. If reabsorbed and recirculated, then this may increase half-life • Increased tubular reabsorption • Enterohepatic recirculation Hydrophilic drugs More likely to be excreted unchanged by the kidney.
    [Show full text]